1. Feasibility of clinical evaluation of individuals with increased risk for HPV‐associated oropharynx cancer
- Author
-
Nicholas Scott‐Wittenborn, Gypsyamber D'Souza, Nafi Aygun, Sakshi R. Tewari, Javad Azadi, Peter Vosler, Zhen Gooi, Vikas Mehta, Wojciech Mydlarz, Melonie Nance, Stefan Mlot, Mihir R. Patel, Marietta Tan, Brett A. Miles, Tanya Troy, and Carole Fakhry
- Subjects
Oropharyngeal Neoplasms ,Otorhinolaryngology ,Squamous Cell Carcinoma of Head and Neck ,Head and Neck Neoplasms ,Papillomavirus Infections ,Carcinoma, Squamous Cell ,Humans ,Human Papillomavirus Viruses ,Prospective Studies ,Papillomaviridae ,Article - Abstract
BACKGROUND: Human papillomavirus-associated oropharynx squamous cell carcinoma (HPV-OPSCC) has no known pre-malignant lesion. While vaccination offers future primary prevention, there is current interest in secondary prevention. The feasibility of clinical evaluation of individuals at increased risk for HPV-OPSCC is unclear. METHODS: Individuals with risk factors for HPV-OPSCC were enrolled in a prospective study (MOUTH). Participants positive for biomarkers associated with HPV-OPSCC were eligible for a clinical evaluation which comprised a head and neck examination and imaging with ultrasound and/or magnetic resonance imaging (MRI). This study was designed to evaluate feasibility of clinical evaluation in a screening study. RESULTS: 384 participants were eligible for clinical evaluation. Of the 384, 204 (53%) completed a head and neck examination or imaging. Of these, 66 (32%) completed MRI (n=51) and/or ultrasound (n=64) studies. CONCLUSIONS: Clinical evaluations, including head and neck examination and imaging, are feasible in the context of a screening study for HPV-OPSCC.
- Published
- 2022
- Full Text
- View/download PDF